Applied Nutrition plc (LSE:APN) shares rose 0.34% to 293.5p in the latest market screen, gaining 1.00p and taking the sports nutrition company's market capitalisation to around £731 million.

The shares are below their 52-week high of around 355p, reached after an upbeat trading update in August.

Key Highlights

In August 2026, Applied Nutrition said FY26 revenue (year to 31 July) rose around 50% to £160 million, ahead of market expectations of £148.4 million.

Adjusted EBITDA was expected to be around £43.3 million, up around 40%.

For FY27, the company guided to revenue of around £205 million, around 28% growth, well ahead of consensus.

Management flagged a modest reduction in margins as whey costs rise and whey-based products grow.

About Applied Nutrition plc

Applied Nutrition plc (LSE:APN) is a Liverpool-based sports nutrition, health and wellness brand, founded in 2014 by Thomas Ryder.

It sells protein powders, drinks, bars and supplements in more than 85 countries, with partnerships including Holland & Barrett and Morrisons.

The company is building North American manufacturing and has a licence for Sour Patch Kids and Swedish Fish branded sports nutrition.

Why Is LSE:APN Up Today?

The 0.34% rise to 293.5p reflects positioning ahead of full-year results, expected in November.

Strong growth guidance supports the investment case.

Investors may see the pullback from highs as an opportunity.

Key Reasons Behind the Uptick

One key factor is strong revenue growth.

A second factor is FY27 guidance ahead of consensus.

Third, US expansion.

Fourth, net cash balance sheet.

Key Growth Catalysts

The most important catalyst for LSE:APN is the full-year results.

US manufacturing and white-label opportunities.

Brand partnerships.

New product launches.

International growth.

Risks

The main risk for LSE:APN is margin pressure from whey costs.

Middle East disruption.

Execution risk in US expansion.

Valuation at around 30 times earnings.

Competition.

Valuation

At 293.5p, Applied Nutrition has a market capitalisation of around £731 million and trades on a P/E of around 30 times.

The key valuation question is whether growth justifies the premium.

Capital Returns

Applied Nutrition does not currently pay a dividend.

It has a net cash position.

What Investors Should Watch Next

Investors in LSE:APN will watch the full-year results and FY27 progress.

Overall, the 0.34% rise in LSE:APN to 293.5p reflects strong growth guidance. At the same time, margin pressure and valuation remain key risks.